Cargando…

Activity of Indatuximab Ravtansine against Triple-Negative Breast Cancer in Preclinical Tumor Models

PURPOSE: Triple-negative breast cancer (TNBC) is related with a poor prognosis as patients do hardly benefit from approved therapies. CD138 (Syndecan-1) is upregulated on human breast cancers. Indatuximab ravtansine (BT062) is an antibody-drug-conjugate that specifically targets CD138-expressing cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schönfeld, Kurt, Herbener, Peter, Zuber, Chantal, Häder, Thomas, Bernöster, Katrin, Uherek, Christoph, Schüttrumpf, Jörg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904230/ https://www.ncbi.nlm.nih.gov/pubmed/29666962 http://dx.doi.org/10.1007/s11095-018-2400-y

Ejemplares similares

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
por: Schönfeld, Kurt, et al.
Publicado: (2017)

Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate
por: Herbener, Peter, et al.
Publicado: (2018)

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
por: Quanz, Maria, et al.
Publicado: (2018)

Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models
por: Rupp, Tristan, et al.
Publicado: (2020)

Covariate analysis of tusamitamab ravtansine, a DM4 anti‐CEACAM5 antibody‐drug conjugate, based on first‐in‐human study
por: Pouzin, Clemence, et al.
Publicado: (2022)

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
por: Tabernero, Josep, et al.
Publicado: (2023)

Tumor Metabolism Is Affected by Obesity in Preclinical Models of Triple-Negative Breast Cancer
por: Yelek, Caner, et al.
Publicado: (2022)

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer
por: Arango, Natalia Paez, et al.
Publicado: (2017)

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
por: Pouzin, Clemence, et al.
Publicado: (2022)

Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
por: Boni, Valentina, et al.
Publicado: (2022)

Characterization of triple‐negative breast cancer preclinical models provides functional evidence of metastatic progression
por: Arroyo‐Crespo, Juan J., et al.
Publicado: (2019)

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody–Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors
por: Hassan, Raffit, et al.
Publicado: (2020)

NK cells engineered to express a GD(2)-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
por: Esser, Ruth, et al.
Publicado: (2012)

Nanoparticles for Chemoimmunotherapy Against Triple-Negative Breast Cancer
por: Liu, Siyan, et al.
Publicado: (2022)

Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer
por: Rashid, Narmeen S., et al.
Publicado: (2021)

Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem
por: Ferraro, Maria Grazia, et al.
Publicado: (2023)

Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors
por: Sulaiman, Andrew, et al.
Publicado: (2017)

Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade
por: Pilones, Karsten A., et al.
Publicado: (2020)

Preclinical evaluation of an (111)In/(225)Ac theranostic targeting transformed MUC1 for triple negative breast cancer
por: Kelly, Vanessa J, et al.
Publicado: (2020)

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer
por: Pitts, Todd M., et al.
Publicado: (2020)

Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells
por: Khandelwal, Soni, et al.
Publicado: (2018)

Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review
por: Maqbool, Mudasir, et al.
Publicado: (2022)

Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC)
por: Cordani, Nicoletta, et al.
Publicado: (2023)

Safety and activity of anti-mesothelin antibody–drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
por: Santin, Alessandro D, et al.
Publicado: (2023)

Triple-Negative Breast Cancer
por: Chu, Quyen D., et al.
Publicado: (2012)

Triple-negative breast cancer
por: Chacón, Reinaldo D, et al.
Publicado: (2010)

Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights
por: Anwar, Mohammed Moustapha, et al.
Publicado: (2020)

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975
por: Tang, Minhong, et al.
Publicado: (2022)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway
por: Helling, Bianca, et al.
Publicado: (2015)

Icaritin enhances the efficacy of cetuximab against triple-negative breast cancer cells
por: Yin, Li, et al.
Publicado: (2020)

Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer
por: Bahman, Fatemah, et al.
Publicado: (2021)

Mechanism-Based Sonodynamic–Chemo Combinations against Triple-Negative Breast Cancer
por: Feng, Xiaolan, et al.
Publicado: (2022)

Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens
por: Srivastava, Nityanand, et al.
Publicado: (2023)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements
por: Hattab, Dima, et al.
Publicado: (2020)

Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort
por: Gonçalves, Homero, et al.
Publicado: (2018)

Unraveling the Genomic-Epigenomic Interaction Landscape in Triple Negative and Non-Triple Negative Breast Cancer
por: Wu, Jiande, et al.
Publicado: (2020)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Characteristics of triple-negative breast cancer
por: de Ruijter, Tim C., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jt42uvnhc5pmjhqmkh4oelouii